Landos Biopharma, Inc. - LABP

SEC Filings Our LABP Tweets

About Gravity Analytica

Recent News

08.11.2026 - Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
08.04.2026 - Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence
07.31.2026 - AbbVie Reports Second-Quarter 2026 Financial Results
07.30.2026 - JUVÉDERM® Day Returns to U.S. on August 19
07.29.2026 - AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
07.29.2026 - AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
07.23.2026 - Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
07.17.2026 - Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients
07.14.2026 - SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development
07.06.2026 - AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recent Filings